# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitti...
RBC Capital analyst Brian Abrahams downgrades Constellation (NASDAQ: CNST) from Outperform to Sector Perform and lowers the ...
Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetic...
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinica...
Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetic...
Jefferies analyst Kelly Shi downgrades Constellation (NASDAQ:CNST) from Buy to Hold and lowers the price target from $53 to ...
Truist Securities analyst Srikripa Devarakonda downgrades Constellation (NASDAQ:CNST) from Buy to Hold and lowers the price ...